Market size, growth to 2033 and clinical trials, side by side.
China is the bigger Mood and Stress Supplements market: $844 Mn against $191 Mn in 2023, about 4.4 times as large.
India grows faster: 11.1% a year, against 9.6%. The gap still grows from $653 Mn to $1.6 Bn by 2033.
Clinical research: 3 active trials in China, 3 in India.
| Measure | ||
|---|---|---|
| Market size, 2023 | $844 Mn | $191 Mn |
| Market size, 2033 projected | $2.1 Bn | $547 Mn |
| Growth a year (CAGR) | 9.6% | 11.1% |
| Money added, 2023–2033 | $1.3 Bn | $356 Mn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $0.60 | $0.13 |
| Active clinical trials | 3 | 3 |
| Full report | China report | India report |
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
China is the bigger Mood and Stress Supplements market: $844 Mn against $191 Mn in 2023, about 4.4 times as large.
India grows faster: 11.1% a year, against 9.6%. The gap still grows from $653 Mn to $1.6 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.